The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.
UK group bets billions on an HER2 project slated for late-line patients and those with lower expression of the target protein.
Probiodrug grabs $15m, but it will need more to fund phase IIb development of its Alzheimer’s candidate, PQ912.
The UK ortho and woundcare group might yet pounce on Nuvasive.
Biogen’s $877m buyout of Nightstar Therapeutics provides yet more evidence that gene therapy is reaching critical mass.
Celgene stock falls 9%, suggesting that an activist campaign to derail its takeover by Bristol-Myers Squibb is reaching critical mass.
GE sells its Biopharma business for $21.4bn, but is its IPO cancelled or merely on hold?
In placing a $1bn bet on the rare disease player Clementia, Ipsen is banking on a lenient US regulator.
The Swiss group picks up Spark Therapeutics for $4.8bn, marking the biggest gene therapy buyout since Novartis’s $8.7bn move on Avexis.